Migraine Drugs Market

Migraine Drugs Market generated a revenue of USD 1,713 Million in 2017 and is forecast to expand at a CAGR of 3.1% during the forecast period (2018-2025), owing to the increasing incidences of migraine.

To have an edge over the competition by knowing the market dynamics and current trends of “migraine drugs market”, request for Sample Report here

Key Drivers and Emerging Trends

Factors such as increasing expenditure on research and development, rising cases of migraines, and growing awareness about treatment options available for migraine are projected to expand the migraine drugs market. Several strategies adopted by leading players which include product innovation, mergers, and acquisitions will offer enormous opportunities to the market. For example, in September 2021, The United States Food and Drug Administration (FDA) approved QULIPTA (atogepant) to AbbVie in order to prevent migraine in adults. Further, the advancement in reimbursement policies for migraine medications coupled with the continuously increasing demand for precision medicines, will boost the market growth. The sedentary lifestyle of millennials has increased the incidences of neurological disorders which is predicted to augment the market growth. For instance, according to the Migraine Research Foundation, more than one billion people worldwide suffer from migraine attacks. The Foundation also states that over 39 million individuals suffer from this neurological condition in the U.S alone. However, the lack of knowledge regarding the proper treatment of migraine will restrain the Migraine Drugs Market size over the upcoming years.

Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report

Regional – Segment Analysis:
North America is anticipated to witness a significant growth in the migraine drugs market over the forecast period, owing to the advent of CGRP therapeutics. Factors including easy access to prescription and over-the-counter drugs and development in healthcare system and the high prevalence of migraine are projected to expand the regional growth. According to the JAMA Network article published in January 2022, in the United States, 17.1% of women and 5.6% of men had migraine symptoms. Thus, higher prevalence is anticipated to propel the migraine therapeutics market share in the United States.

In case, any of your pain points areas are not covered in the current scope of this report, Request for Free Customization here

Top Market Players

Various notable players operating in the global migraine drugs market include Abbott Laboratories, Aegis Therapeutics, LLC, Aerial Biopharma LLC, Alder Biopharmaceuticals Inc., Amgen Inc, Astellas Pharma, AstraZeneca, Johnsons and Johnsons, Eisai Co Ltd, Eli Lily & Co and others.

Key Developments:

• • In February 2022, Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. It is recommended as the 75 mg dose of Rimegepant (available as an orally dissolving tablet) for marketing authorization for both the acute treatment of migraine with or without aura in adults and the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
  • In January 2022, BioDelivery Sciences launched a new drug Elyxyb (celecoxib oral solution), a fast-acting liquid. It is one of the first Food and Drug Administration-approved ready-to-use oral solutions for adults in the acute treatment of migraine, with or without aura.

Segments covered in the Report:

The global migraine drugs market has been segmented on the basis of drug type, route of administration, end user and key geographies. Based on the drug type, the market comprises of abortive drugs and preventive drugs. Based on route of administration, the market is classified into Oral, Injectables and Others. Based on end user market is segmented into Hospital pharmacies, retail pharmacies and others.

This research report “global migraine drugs market” provides in-depth analysis of the migraine drugs market across the globe based on drug type, route of administration, end user and major geographies for the forecast period from 2018 to 2025. The report highlights the major market drivers propelling the growth as well as challenges faced by market participants. The research report provides market size and forecast for migraine drugs market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

For detailed scope of the “migraine drugs market” report request a Sample Copy of the report

Key questions answered in this research report:
1. At what pace is migraine drugs market growing worldwide? What will be growth trend in future?
2. What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the future?
3. What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in the migraine drugs market?
4. What are the various application areas and how they are poised to grow?

The global migraine drugs market has been segmented based on drug type, route of administration, end user and geography:

Global Migraine Drugs Market, by Drug Type
• Abortive Drugs
• Preventive Drugs

Global Migraine Drug Market, by Route of Administration
• Oral
• Injectables
• Others (Nasal Spray, Transdermal Path, etc.)

Global Migraine Drugs Market, by End User
• Hospitals Pharmacies
• Retail Pharmacies
• Others

Global Migraine Drug Market, by Region

• North America Migraine Drug Market (Option 1: As a part of the free 25% customization)
  • By Drug Type
  • By Route of Administration
  • By End User
  • US Market All-Up
  • Canada Market All-Up
• Europe Migraine Drug Market (Option 2: As a part of the free 25% customization)
  • By Drug Type
  • By Route of Administration
  • By End User
  • UK Market All-Up
  • Germany Market All-Up
  • France Market All-Up
  • Spain Market All-Up
  • Rest of Europe Market All-Up
• Asia-Pacific Migraine Drug Market (Option 3: As a part of the free 25% customization)
  • By Drug Type
  • By Route of Administration
  • By End User
  • China Market All-Up
  • India Market All-Up
  • Japan Market All-Up
  • Rest of APAC Market All-Up
• RoW Migraine Drug Market (Option 4: As a part of the free 25% customization)
  • By Drug Type
  • By Route of Administration
  • By End User
  • Brazil Market All-Up
  • South Africa Market All-Up
  • Saudi Arabia Market All-Up
  • UAE Market All-Up
  • Rest of world (remaining countries of the LAMEA region) Market All-Up

Global Migraine Drug Market Competitive Landscape

• Major Players and their Key Strategies
• New Drug Launches
• Mergers and Acquisitions
• Collaborations, Partnerships, Agreements and Joint Ventures

Leading Market Players
• Abbott Laboratories
• Aegis Therapeutics, LLC
• Aerial Biopharma LLC
• Alder Biopharmaceuticals Inc.,
• Amgen Inc Lucibel SA
• Astellas Pharma.
• AstraZeneca Velmenni OÜ
• Johnsons and Johnsons
• Eisai Co Ltd
• Eli Lily & Co

Other prominent players in the market which can be profiled as a part of customization:
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.,